analyzeportfolio
Nasdaq · Consumer Staples

PETMED EXPRESS INC (PETS)

As-reported financials and SEC filings for PETMED EXPRESS INC. The latest annual period is FY2026. The latest reported quarter is Q1 FY2027. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About PETMED EXPRESS INC

PetMed Express Inc operates as a direct-to-consumer retailer of pet health and wellness products through its websites and mobile applications. The company offers prescription and non-prescription medications, pet foods, supplements, and supplies for dogs, cats, and horses, fulfilling orders with licensed pharmacists and veterinary approval. It serves pet owners across the United States, providing customer support and additional services such as telemedicine consultations and employer-offered pet benefits.

Snapshot

Revenue
$179.0M
Revenue growth (YoY)
-21.1%
Net income
$-57.3M
Diluted EPS
$-2.74
Gross margin
Operating margin
-32.8%
Net margin
-32.0%
FCF margin
-18.4%
ROE
-197.9%
net income / fiscal-year-end equity
P/E
trailing when available, otherwise FY EPS
Market cap
$38.8M
Long-term debt / equity
non-current term debt only

Fundamentals are from SEC filings for FY2026, the latest annual period (ended March 31, 2026). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Petmed Express

  • Revenue fell 21.1% to $179M in FY2026, after a 17.2% decline the year before.
  • Operating margin is now a 32.8% loss in FY2026, from 8.9% in FY2022.
  • Most recent quarter Q1 FY2027: revenue $41M, down 19.9% from Q1 FY2026.
  • Free cash flow was negative $33M in FY2026.
  • Net loss widened to $57M in FY2026, from $6M in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Petmed Express’s fundamentals sit among the 113 Consumer Staples companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin-32.8%
5th percentile of 100
Net margin-32.0%
6th percentile of 105
FCF margin-18.4%
5th percentile of 99
Revenue growth (YoY)-21.1%
6th percentile of 110
ROE-197.9%
5th percentile of 99
Short interest5.19d
68th percentile of 111

Petmed Express’s operating margin of -32.8% ranks in the 5th percentile of the 100 Consumer Staples companies reporting it. Petmed Express’s FCF margin of -18.4% ranks in the 5th percentile of the 99 Consumer Staples companies reporting it. Petmed Express’s return on equity of -197.9% ranks in the 5th percentile of the 99 Consumer Staples companies reporting it.

1 reported insider purchase (code P) totaling $43,725 in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 2 quant / multi-strat books among the superinvestors we track; no conviction manager currently reports a position.

Conviction investors
0
+2 quant / multi-strat
Initiated / added
0
0 new, 0 added
Reduced / exited
2
2 trimmed, 0 exited
Combined position
$2.3M
reported long value
InvestorAs ofPosition valueSharesChange
Renaissance TechnologiesquantQ2 2026$2.2M1.1MReduced
Citadel AdvisorsquantQ2 2026$142,32474.1KReduced

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
1
1 insider
Bought (90d)
$44K
code P value
Sells (90d)
0
Reported activity
Net buying
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-06-08
filed 2026-06-09
NINA CAPITAL HOLDINGS INC.10% ownerBuy25.0K$1.75$44K

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
576.6K
settled 2026-08-14
Change vs prior
-12.3%
vs previous settlement
Days to cover
5.19
at avg daily volume
Avg daily volume
111.1K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-14576.6K-12.3%5.19
2026-07-31657.4K-28.1%6.82
2026-07-15914.0K-43.5%3.72
2026-06-301.6M+164.2%1.00
2026-06-15612.3K+15.4%2.32
2026-05-29530.5K-8.4%3.69
2026-05-15579.3K-8.8%10.71
2026-04-30635.5K-21.7%7.87

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2026FY2025FY2024FY2023FY2022
Revenue$179.0M$227.0M$274.1M$247.6M$272.3M
Gross profit$69.1M$84.8M$76.5M$76.9M
Operating income$-58.7M$-1.5M$-8.2M$6.1M$24.3M
Net income$-57.3M$-6.3M$-7.5M$5.1M$18.7M
Diluted EPS$-2.74$-0.30$-0.37$0.25$0.92

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

 FY2026FY2025FY2024FY2023FY2022
Cash and equivalents$21.4M$54.7M$55.3M$104.1M$111.1M
Current assets$43.6M$78.9M$93.6M$130.4M$151.0M
Total assets$81.2M$148.7M$169.9M$167.5M$179.7M
Current liabilities$52.0M$62.8M$72.2M$57.5M$56.2M
Long-term debt
Total liabilities$52.3M$63.6M$73.2M$57.5M$56.2M
Total equity$28.9M$85.1M$96.7M$110.0M$123.5M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2026FY2025FY2024FY2023FY2022
Operating cash flow$-28.4M$4.7M$4.3M$27.8M$18.5M
Capital expenditure$4.6M$5.1M$4.5M$5.3M$1.8M
Free cash flow$-33.0M$-395,000$-194,000$22.5M$16.7M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q1 FY2027$41.0M-19.9%$-6.1M$-0.28
Q4 FY2026$42.8M-15.6%$-4.1M$-0.19
Q3 FY2026$40.7M-21.7%$-10.6M$-0.50
Q2 FY2026$44.4M-23.6%$-8.5M$-0.41
Q1 FY2026$51.2M-22.7%$-34.2M$-1.65
Q4 FY2025$50.8M-22.0%$-11.6M$-0.60
Q3 FY2025$52.0M-18.4%$-707,000$-0.03
Q2 FY2025$58.0M-16.4%$2.3M$0.11

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorConsumer Staples
SIC industryRetail-Drug Stores and Proprietary Stores
Latest annual periodFY2026 (ended March 31, 2026)
Latest reported quarterQ1 FY2027 (ended June 30, 2026)
Oldest indexed filing2005
SEC CIK1040130

Selected SEC filings

10-K2026-06-02
View on EDGAR →
10-K2025-10-14
View on EDGAR →
10-Q2026-08-13
View on EDGAR →
10-Q2026-02-05
View on EDGAR →
10-Q2025-12-19
View on EDGAR →
10-Q2025-12-19
View on EDGAR →
8-K2026-08-13
View on EDGAR →
8-K2026-08-12
View on EDGAR →

Largest Consumer Staples peers

All Consumer Staples companies →

Monitor PETS

Get an alert when Petmed Express files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor PETS free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.